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Direct Pulmonary Vein Ablation With Stenosis Prevention Therapy. Introduction: The dom-
inant location of electrical triggers for initiating atrial fibrillation (AF) originates from the muscle sleeves
inside pulmonary veins (PVs). Currently, radiofrequency ablation (RFA) is performed outside of the PVs
to isolate, rather than directly ablate these tissues, due to the risk of intraluminal PV stenosis.
Methods: In 4 chronic canine experiments, we performed direct PV muscle sleeve RFA ± postablation
drug-coated balloon (DCB) treatment with paclitaxel/everolimus. Of the 4 PVs, 2 PVs were ablated and
treated with DCB, 1 PV was ablated without DCB treatment (positive control), and 1 PV was left as a
negative control. Local electrograms were assessed in PVs for near-field signals and were targeted for
ablation. After 12–14 weeks survival, PVs were interrogated for absence of near-field PV potentials, and
each PV was assessed for stenosis.
Results: All canines survived the study period without cardiorespiratory complications, and remained
ambulatory. In all canines, PVs that were ablated and treated with DCB remained without any significant
intraluminal stenosis. In contrast, PVs that were ablated and not treated with DCB showed near or complete
intraluminal stenosis. At terminal study, PV potentials remained undetectable. A blinded, histologic analysis
demonstrated that ablated PVs without DCB treatment had extensive thrombus, fibrin, mineralization, and
elastin disruption.
Conclusion: Our chronic canine data suggest that direct PV tissue ablation without subsequent stenosis
is feasible with the use of postablation DCBs. (J Cardiovasc Electrophysiol, Vol. 26, pp. 1000-1006, September
2015)
anti-proliferative agent, atrial fibrillation, catheter ablation, neointimal hyperplasia, pulmonary vein stenosis,
pulmonary vein isolation
Introduction
Electrical activity originates within pulmonary vein (PV)
muscle sleeves, which are complex extensions of left atrial
(LA) myocardium that permeates into the veins with a vari-
able fiber thickness and orientation.1 In a landmark study in
1998 by Haı¨ssaguerre et al., PV muscle was shown to harbor
electrical triggers that can spontaneously initiate atrial
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fibrillation (AF).2 These triggers were mapped inside the PV
and subsequently targeted for direct radiofrequency ablation
(RFA).2 The mainstay of catheter-based treatment for AF
has evolved to performance of circular ablation around the
outside of the PV ostia to create electrical isolation to the
LA,3 rather than a direct ablation of the triggers inside
the PVs in order to minimize the potential for development
of PV stenosis (Fig. 1). Unfortunately, paroxysmal AF
ablation is associated with a high rate of recurrence, and
randomized controlled trials have demonstrated 66–86%
efficacy at about 12 months postablation.4 Therefore, a
critical unmet need exists to improve the efficacy of AF
ablation, while maintaining procedural safety.
Using a PV isolation approach outside of the PV itself,
the high frequency of AF recurrence is due to gaps within
the ablation lesions, and electrical reconnection to the
LA.4,5 A more effective ablation strategy would involve
direct ablation of these triggers inside the PV. However, this
approach is currently avoided because of the known compli-
cation of potentially life-threatening PV stenosis.6 Although
the exact mechanism for radiofrequency (RF)-induced PV
stenosis remains undefined, canine studies have shown that
histologic changes of neointimal hyperplasia, elastic lamina
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Figure 1. Illustration of pulmonary vein ablation versus isolation and potential for atrial fibrillation recurrence. (A) Shows a two chamber view of both
right and left atria is shown, with en face view of the four ostia of the pulmonary veins (PVs). The left superior pulmonary vein is shown with the escape of
electrical activity emerging from the PV myocardium, serving as a trigger for atrial fibrillation (AF). (B) Illustrates that the electrical triggers within the PVs
are present, but are now isolated from the rest of the atria, and thus preventing triggering of AF. The circular radiofrequency ablation lesions are outside the
ostia of the PVs. (C) Shows an example of direct PV myocardial tissue ablation is shown in the left superior pulmonary vein. The ablation catheter is shown
ablating myocardium that exists within the lumen of the vein. (D) Shows comparison of postablation scenarios depending on the type of ablation method
used. The right superior pulmonary vein has undergone PV isolation, and a complete circular lesion around the ostia persists. Note that the electrically
active myocardium inside the PVs remains viable. The left superior pulmonary vein shows the concern with the PV isolation approach, as a gap in ablation
will allow for escape electrical activity and the potential for AF recurrence. The right and left lower pulmonary veins are shown post direct PV myocardial
ablation. Because of direct ablation of these muscle sleeves, the electrical trigger for AF is eliminated.
proliferation, thrombus, and collagen deposition occur.7
In a recent porcine study, successful antagonism of the
neointimal proliferation process by a paclitaxel-coated
scoring balloon was demonstrated.8
We hypothesized that postablation treatment with an an-
tiproliferative agent can prevent PV stenosis. We tested this
hypothesis by performing RFA within canine PVs along with
postablation delivery of drug via a coated balloon.
Methods
Animal study protocol, surgical preparation,
and monitoring
Our experimental protocol was conducted according to the
guidelines and regulations set forth by the Mayo Clinic In-
stitutional Animal Care Use Committee (IACUC) (protocol
#A48913). Five healthy, male mongrel dogs (30–40 kg) un-
derwent experimental study of the four PVs draining into the
LA, left superior pulmonary vein (LSPV), left inferior pul-
monary vein (LIPV), right superior pulmonary vein (RSPV),
and right inferior pulmonary vein (RIPV).
Canines were fasted 12 hours prior to each experimental
procedure. Subcutaneous buprenorphine (0.15 mg/kg) and
50 mg/kg cefazolin were given intravenously (IV) 20 minutes
prior to procedure for pain control and surgical prophylaxis.
Canines were prepped in sterile fashion. Anesthetic induction
for intubation was performed with the use of IV ketamine
(10 mg/kg) and diazepam (0.5 mg/kg). Isoflurane (1–3%)
was used for maintenance of anesthesia with volume-cycled
ventilation. Continuous monitoring of arterial blood pres-
sure, ECG, and level of anesthesia occurred throughout the
procedure. Postprocedure, animals were monitored daily for
pulmonary distress, hemoptysis, and bleeding. Aside from
intra-procedural heparin, no antiplatelet or anticoagulation
medications were used at any time during the study.
Vascular Access, Imaging, and Recording
A standard cut-down technique was utilized for access to
the femoral arteries and veins, as well as the external jugular
veins for sheath placement. An 18 gauge needle was placed
in each vessel, a guidewire was introduced, and a sheath
was advanced over the wire. A 12 Fr sheath was placed
in the right external jugular vein for ICE imaging (Acuson
Ultrasound SC2000, Siemens, Erlangen, Germany) with
a 10 Fr, 5.5–10 MHz steerable tip catheter. A 9 Fr sheath
was placed in the right femoral artery for blood pressure
recordings. Fluoroscopic imaging of the cardiac anatomy
was performed using a CathLab Siemens ArtisZee X-ray
machine (Siemens). All EP recordings were performed
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Figure 2. Schematic drawing of experi-
mental approach to ablation and antis-
tenosis drug application in canine stud-
ies. Timeline and treatment regimen for
each of the canine pulmonary veins is
shown. LSPV = left superior pulmonary
vein; LIPV = left inferior pulmonary
vein; RSPV = right superior pulmonary
vein; RIPV = right inferior pulmonary
vein; RFA = radiofrequency ablation.
“Drug” denotes use of drug-coated bal-
loon (paclitaxel or everolimus) adminis-
tered postablation.
using the Prucka Cardiolab system (GE Healthcare Clinical
Systems, Milwaukee, WI, USA). Pacing was performed
with the use of a Bloom DTU-215B EP stimulator (Fisher
Medical Technologies Inc., Broomfield, CO, USA). Bipolar
signals were recorded with low and high pass filters set at 30
and 500 Hz, respectively, and a 60 Hz notch filter. Cardiac
ablation was performed with the Maestro 3000 system
(Boston Scientific, Marlborough, MA, USA).
Experimental Study
For each canine, an intervention strategy for each of the
4 PVs included: (1) one PV without ablation and without
drug-coated balloon (DCB) (negative control), (2) one PV
with RFA only (positive control), and (3) two remaining PVs
served as treatment vessels for combined ablation and sub-
sequent DCB delivery of an antiproliferative agent (Fig. 2).
Each canine had an initial study performed that included flu-
oroscopic venography, intracardiac echocardiography (ICE)
with Doppler imaging and measurements of the PVs, elec-
trophysiologic (EP) assessment, and ablation/DCB interven-
tion. Four canines completed the initial study and were
survived an additional 12–14 weeks for a second procedure (a
fifth canine exsanguinated prior to the experimental portion
of the study; this was due to a defective transseptal sheath,
which led to the transseptal needle piercing out the right side
of the sheath and cannulating the aorta).
Prior to transseptal puncture, unfractionated heparin was
given intravenously at 100 U/kg as a bolus and followed by
30 U/kg/hr for the rest of the surgical procedure. The LA
was then accessed with the use of a Brockenbrough needle
through the atrial septum under ICE and fluoroscopic guid-
ance, and the sheath was advanced into a stable position
into the LA for easy PV access. Prior to ablation, PVs were
imaged with ICE and LA contrast venography. PV ostial
diameter and flow velocities were measured.
Using a combination of intracardiac ultrasound and an-
giography, the PV ostium and number was identified. A
Figure 3. Direct pulmonary vein myocardium ablation. The local electro-
gram of the pulmonary vein myocardium of the left superior pulmonary
vein of canine #4. Panel (A) shows a multi-component electrogram with
near-field PV potential and a far-field left atrial signal pre-ablation with
radiofrequency energy. Panel (B) from the same site shows decrease in the
near-field PV signal during ablation. Panel (C) shows complete elimination
of the near-field PV potential, and the remaining far-field left atrial signal.
quadripolar, Blazer II ablation catheter (7Fr, 4 mm tip, 2.5
mm electrode spacing) (Boston Scientific) was utilized for
both mapping and ablating the electrical signals of the PV
muscle sleeves. Ablation was performed in a point-to-point
manner inside the PVs wherever near-field signals were
found. These sites were treated with 120 seconds applica-
tions of RF energy at 30 Watts/50 °C. The endpoint of abla-
tion at each site within the vein was the loss of the local PV
near-field signal (Fig. 3). The loss of signal was either from
complete tissue obliteration, fragmentation, or only residual
far-field signals. In doubtful cases, pacing from the ablation
electrode was done to be sure that there was no capture of
the PV myocardium.
After ablation was completed, 2 PVs underwent DCB
treatment. This was performed with the use of an over-the-
wire balloon catheter directed to the target vessel (provided
by Boston Scientific). The balloons were coated with either
paclitaxel or everolimus (10 mm diameter; 30 mm in length)
and covered the complete area that was ablated. Each balloon
was expanded to contact the wall of PVs at 3–6 atmospheres
(atm) of pressure for an application time of 60 seconds.
ICE with Doppler was performed to obtain ostial diame-
ter and PV velocity (Fig. 4). After 12–14 weeks survival,
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Figure 4. Intracardiac echocardiographic imaging with Doppler color flow demonstrates degree of vein stenosis and flow velocity within the pulmonary
vein. Panel (A) shows a color Doppler image of an LIPV that was ablated and treated with an everolimus-coated balloon (canine #5). In the same canine,
Panel (B) shows a color Doppler of the LSPV (ablated only), showing severe stenosis along the vein, and high Doppler velocity evident from the noted
aliasing. This aliasing correlated with an increasing velocity from 0.64 to 1.2 m/s.
Figure 5. Venographic and anatomic
demonstration of pulmonary veins post
ablation and drug treatment. Panel (A)
shows gross anatomic sample showing the
stenotic RIPV (positive control; canine
#1), while the rest of the PVs (LIPV –
negative control; LSPV and RSPV- ab-
lation + DCB) are grossly normal.
Panel (B) shows the intraluminal contents
of the stenotic RIPV (positive control; ca-
nine #1) show thrombus, fibrin, collagen
deposition, and mineralization. The re-
maining 3 PVs show almost no intralumi-
nal contents or narrowing; these include
the two PVs that were ablated and treated
with DCB (RSPV and LSPV with pacli-
taxel) and the negative control (LIPV).
Panel (C) shows a left atrial venogram
that illustrates the outline of the canine
RSPV. The occluded RIPV is not visual-
ized past the ostium. Panel (D) depicts a
selective venogram of a patent LSPV.
a second procedure was performed (terminal study). PV
venography was repeated to evaluate for stenosis (Fig. 5).
All PVs were interrogated to ensure persistent elimination of
PV potentials.
Postmortem Analysis
After the terminal study, the animals were euthanized
under anesthesia with direct current induction of ventric-
ular fibrillation to the ventricle. Necropsy was performed
to assess for gross damage to vital structures. Postmortem
en bloc heart and lungs were formalin fixed under pressure
with 10% neutral buffered formalin at 25 mmHg for at least
2 hours. Gross anatomic evaluation of the PVs was performed
(Fig. 5). Tissue was stained with hematoxylin and eosin
and Movat’s pentachrome to assess for intraluminal stenosis
(Fig. 5) (American Preclinical Services, Bloomington, MN,
USA). The interpreting pathologist was blinded to PV treat-
ment.
Statistical Analysis
Statistical analysis was performed using SAS software
(Cary, NC, USA). Measurements of PV ostial diameter (cm)
and flow velocity (m/s) were performed in each PV prior
to ablation and at terminal study. The percent change from
baseline was calculated for each PV. For purposes of compar-
ative statistical analysis, PVs were analyzed as independent
variables, and averaged in groups according to intervention
(negative control, positive control, or treatment veins). Gen-
eralized Estimating Equation models were used to compare
the average percent change in ostial diameter (cm) and flow
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TABLE 1
Experimental Treatment Strategy Used for Canine Pulmonary Vein Ablation and Drug-Coated Balloon Treatment
Canine RSPV RIPV LSPV LIPV DCB Survival Complications
#1 Ablation + DCB* Ablation only Ablation + DCB* No treatment Paclitaxel 12 weeks None
#2 No treatment Ablation + DCB Ablation only Ablation + DCB Everolimus 14 weeks None
#3 N/A N/A N/A N/A N/A αDied αTransseptal complication
#4 Ablation + DCB No treatment Ablation only Ablation + DCB Paclitaxel 14 weeks None
#5 Ablation + DCB No treatment Ablation only Ablation + DCB Everolimus 12 weeks None
DCB = drug-coated balloon; LIPV = left inferior pulmonary vein; LSPV = left superior pulmonary vein; RIPV = right inferior pulmonary vein; RSPV =
right superior pulmonary vein. αDog #3 died from a defect in the transseptal sheath causing the needle to exit prematurely and pierce the aorta.
*Canine #1 had two DCB applications to each treated PV to ensure covering the ablation lesion.
velocity (m/s) between the groups. These models were used
to account for multiple measures from each dog. The thresh-
old for statistical significance was a two-tailed P value of
<0.05. All data are shown as mean ± standard deviation
unless stated.
Results
Assessment of Pulmonary Vein Patency
In four survival canine experiments, we performed di-
rect PV ablation in a total of 12 PVs (Table 1), with the
remaining 4 serving as controls. All 4 canines survived the
follow-up period (12–14 weeks) without any respiratory dis-
tress, hemoptysis, and remained ambulatory. Of the 12 PVs
that underwent RFA, 8 were ablated and treated with a DCB
(4 with paclitaxel; 4 with everolimus). These 8 PVs remained
grossly patent and showed only minimal to no intraluminal
narrowing. In contrast, the ablation-only PVs were severely
stenosed or completely occluded. Figure 5 shows an exam-
ple of two PVs in the same canine (canine #5) using ICE
with Doppler imaging. The relatively patent LIPV (RFA +
everolimus) shows laminar flow. This is in contrast to the
severely stenosed LSPV (ablation only) that shows a high
velocity jet with aliasing.
We measured the ostial diameter (cm) and flow velocity
(m/s) in each PV prior to ablation and at the time of termi-
nal study (Table 2). We compared the average change from
baseline in ostial diameter and flow velocity among groups
of PVs according to intervention (ablation only, ablation +
DCB, and no intervention) (Table 3). In PVs that were ab-
lated and treated with a DCB (n = 8), an average increase
in ostial diameter of 4.7 ± 23.2% was seen. In contrast, PVs
that underwent ablation only (n = 4) had an average reduc-
tion of 65.2 ± 26.7%. The difference between these groups
was statistically significant (P < 0.001). In the negative con-
trol PVs (n = 4), an average increase in ostial diameter of
47.6 ± 33.4% was found, and this was significant when
compared to the ablation + DCB group (P < 0.001). In
evaluating the baseline to terminal study PV flow velocities,
the ablation only group increased 12.1 ± 49.8%. There was
no statistically significant difference when compared to the
PV ablation + DCB group, where a decrease in velocity of
28.1 ± 33.3% was found (P = 0.08). The negative control
group had a decrease in flow velocity of 20.2 ± 38%, and no
significant difference was found when compared to the abla-
tion + DCB group (P = 0.44).
TABLE 2
Canine Pulmonary Vein Ostia Diameter and Flow Velocities Determined
from Intracardiac Echocardiography and Doppler Ultrasound
Measurement Pre-Intervention End Study Treatment
Canine #1
LSPV Ostial diameter 0.9 cm 0.65 cm Ablation + DCB
LSPV Flow velocity 0.52 m/s 0.61 m/s Ablation + DCB
LIPV Ostial diameter 0.53 cm 0.83 cm No ablation
LIPV Flow velocity 0.41 m/s 0.48 m/s No ablation
RSPV Ostial diameter 0.92 cm 0.97 cm Ablation + DCB
RSPV Flow velocity 0.68 m/s 0.34 m/s Ablation + DCB
RIPV Ostial diameter 1.14 cm 0 cm Ablation only
RIPV Flow velocity 0.61 m/s N/A Ablation only
Canine #2
LSPV Ostial diameter 0.9 cm 0.57 cm Ablation only
LSPV Flow velocity 0.64 m/s 0.43 m/s Ablation only
LIPV Ostial diameter 0.75 cm 0.77 cm Ablation + DCB
LIPV Flow velocity 0.79 m/s 0.28 m/s Ablation + DCB
RSPV Ostial diameter 1.02 cm 1.77 cm No ablation
RSPV Flow velocity 0.55 m/s 0.34 m/s No ablation
RIPV Ostial diameter 0.90 cm 1.28 cm Ablation + DCB
RIPV Flow velocity 0.6 m/s 0.35 m/s Ablation + DCB
Canine #3
LSPV Ostial diameter 0.78 cm 0.35 cm Ablation only
LSPV Flow velocity 0.60 m/s 0.62 m/s Ablation only
LIPV Ostial diameter 0.98 cm 0.98 cm Ablation + DCB
LIPV Flow velocity 0.47 m/s 0.40 m/s Ablation + DCB
RSPV Ostial diameter 1.35 cm 1.03 cm Ablation + DCB
RSPV Flow velocity 0.67 m/s 0.22 m/s Ablation + DCB
RIPV Ostial diameter 1.46 cm 1.44 cm No ablation
RIPV Flow velocity 0.82 m/s 0.29 m/s No ablation
Canine #4
LSPV Ostial diameter 0.96 cm 0.30 cm Ablation only
LSPV Flow velocity 0.35 m/s 0.58 m/s Ablation only
LIPV Ostial diameter 0.74 cm 0.85 cm Ablation + DCB
LIPV Flow velocity 0.38 m/s 0.44 m/s Ablation + DCB
RSPV Ostial diameter 1.36 cm 1.68 cm Ablation + DCB
RSPV Flow velocity 0.30 m/s 0.24 m/s Ablation + DCB
RIPV Ostial diameter 0.99 cm 1.60 cm No ablation
RIPV Flow velocity 0.40 m/s 0.42 m/s No ablation
LIPV = left inferior pulmonary vein; LSPV = left superior pulmonary vein;
PV = pulmonary vein; RIPV = right inferior pulmonary vein; RSPV = right
superior pulmonary vein.
Acute and Chronic Assessment of Direct Pulmonary Vein
Ablation Efficacy
In all 4 chronic canines, all 16 veins (LSPV, LIPV, RSPV,
and RIPV in each canine) showed electrically active mus-
cle tissue upon PV interrogation. In each PV targeted for
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TABLE 3
Analysis of Pulmonary Vein Ostial Diameter and Pulmonary Vein Flow Velocity Changes Taken Prior to Ablation and at Terminal Study
Average % Change Average % Change
Intervention Group in Ostial Diameter SD P Value in Flow Velocity SD P Value
Ablated only –652 26.7 <0.001 12.1 49.8 0.08
No intervention 476 33.4 <0.001 –20.2 38 0.44
Ablated + DCB 47 23.2 – –28.1 33.3 –
The average percent change of ostial diameter and pulmonary vein flow velocity are shown. Measurements were taken at each PV prior to ablation and at
the time of terminal study. The average percent change was calculated according to intervention, and compared across groups. Student’s t-test and P < 0.05.
Comparisons were made between Ablated + DCB group to the negative (no intervention) and positive (ablation only) control groups using a Student’s t-test.
DCB = drug-coated balloon.
ablation, 100% (12/12) had complete PV potential elimina-
tion and conduction block. After 12–14 weeks of survival,
each PV that was ablated (12/12) remained without PV po-
tential and without electrical reconnection, with persistent
conduction block (canine #1 RIPV was completed occluded
and electrical assessment was not performed at terminal
study).
Gross Anatomic and Histologic Findings
At necropsy, no gross signs of vital organ damage were
seen. All canine PVs were examined after disconnection
from the lungs (canine #1- Fig. 5). A histologic analysis
was performed between canine #1 (paclitaxel DCB) and #2
(everolimus DCB). The sectioned PVs showed similar his-
tologic findings that reflected minor fibrous tissue replace-
ment. In contrast, the ablation only PVs were found to have
intraluminal fibrin, elastin disruption, thrombus, and miner-
alization. An example of 4 PVs sectioned distal to the os is
shown in Figure 5.
Discussion
The main finding of our study is that direct RFA inside PV
muscle sleeves can be performed while maintaining patency
in canines survived at least 3 months. In addition, direct PV
ablation is effective at eliminating electrical triggers for at
least 3 months. Furthermore, this proof-of-concept approach
held independent of the type of DCB used. To the best of
our knowledge, this is the first reported experiment where a
DCB was used post-RFA to prevent stenosis in PVs.
Interpretation of Our Results
In addition to gross evaluation of the PVs, we assessed
the degree of stenosis/narrowing by comparing the change
at terminal study to that at baseline by measuring PV ostial
diameter (cm) and flow velocity (m/s). As expected, RFA
within the PVs led to severe narrowing or even complete
occlusion. In comparing the ablation only PV group, to the
ablation + DCB group, we found >10-fold reduction in
ostial diameter (60% vs. 5%).
We found a difference in PV flow velocity when com-
paring the ablation only group (+ 12%) with the ablation
+ DCB group (–28%), although this was not significant
(P = 0.14). This may be due to being underpowered to detect a
difference, or because of error associated with small varia-
tions in technique of reproducibly lining up the pulse wave
Doppler in these small canine PVs. In future studies, we
wish to improve the fidelity of our quantification methods,
but also to pursue a clinical correlation to PV stenosis. Human
studies using radionuclide imaging have suggested that a lu-
minal narrowing of 80% or an associated 5 mmHg LA-PV
pressure gradient was found to be associated with a lung
perfusion defect.9
We found an increase in PV ostial diameter of 48% in
our negative control group of PVs. Consistent with the in-
crease in ostial size, there was a concomitant decrease in PV
flow velocity (m/s) of 20% from baseline, measured at the
terminal study. The most likely explanation for this finding
is that in ablating PV myocardium, the vein may become
aneurysmal. However, this is not typically seen because this
is usually offset by endothelial proliferation. Thus, if the
endothelial proliferation is prevented, such as in the case
of our experiments with the use of antiproliferative agents
such as paclitaxel or everolimus, then it is likely that we are
observing the unopposed dilatation.
Potential Mechanism of Pulmonary Vein Stenosis
and Action of Antiproliferative Agents
The mechanism of PV stenosis remains undefined. This
has been previously examined in animal and human stud-
ies. The acute thermal effects of RFA on canine PVs were
studied by Kok et al., and suggested that acute PV stenosis
may be due to collagen denaturation and vessel contraction.10
However, the investigators had removed the muscular sleeves
from the PVs prior to testing, and thus the thermal effect on
the natural PV could not be addressed. The authors note this
effect is in contrast to that in chronic PV stenosis, which is
suggested to result from a rigorous inflammatory response at
the site of ablation.7,10 Taylor et al. performed RFA within
PVs to evaluate histologic changes over time.7 At 1–2 months
follow-up they showed intimal thickening, thrombus forma-
tion, altered smooth muscle/collagen matrix, and elastic lam-
inae proliferation occurred.7 Histologic analysis on patients
with congenital PV stenosis has been performed. At post-
mortem evaluation, a stenosed PV was noted to have promi-
nent intimal proliferation, along with collagen, and a disarray
of elastic fibers.11
Paclitaxel-coated balloons have been shown to prevent
neointimal hyperproliferation, and are currently being used
to prevent coronary and peripheral arterial restenosis.12 The
activity of paclitaxel is based on blocking microtubule as-
sembly, cell division and migration, and disrupting over-
all cellular proliferation.12 Everolimus works by inhibiting
smooth muscle proliferation and migration by halting the
cell cycle in the G1 phase, and inhibiting the mammalian
target of rapamycin (mTOR).13,14 In keeping with our his-
tologic analysis of stenosed PVs, we found the presence of
fibrin, thrombus, calcification, elastic laminae changes, and
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neointimal proliferation. It is tempting to speculate that the
local uptake of either drug at the site of tissue ablation in-
terrupts the inflammatory response, especially tissue hyper-
proliferation, which in concert with fibrin and thrombus can
lead towards intraluminal stenosis. However, further study is
needed before this hypothesis can be supported.
Conclusions
Our data suggest that RFA of muscle sleeves inside PVs
while maintaining luminal patency is feasible, and is effective
in maintaining conduction block in canines survived at least
3 months.
Clinical Implications
These preliminary findings may form the basis for a com-
bined PV isolation and ablation approach to increase the
efficacy and safety of AF ablation without the complication
of stenosis.
Limitations
Our testing was performed in healthy canines. Although
not the aim of this early, proof-of-concept experiment, the
creation of sustained PV exit block without stenosis remains
to be tested in an animal model of AF. We did not specify a
randomized treatment approach to PVs a priori. In addition
to randomization of treatment approach, these early findings
should be confirmed in a larger number of canines, and over
a longer survival period. While we hypothesized that the
effect of paclitaxel/everolimus is to block neointimal tissue
proliferation, we have no evidence to demonstrate that this
is the mechanism by which PV stenosis is prevented. Fur-
ther study to delineate the histologic changes postablation is
needed. Furthermore, we have no data on the uptake of these
drugs into PV tissue, nor do we have any data if there is a
dose-dependency of this effect.
As with all large animal studies, we cannot extrapolate
these findings to ablation in human PVs, as the inflammatory
response and uptake of these drugs may behave in a different
manner. Finally, in order to translate this approach to improve
AF therapies, we will most likely need to employ a com-
bined approach of PV ablation along with isolation to ablate
the trigger as well as the antrum-ostial interface. While we
presume that direct pulmonary vein ablation, as with direct
ablation of arrhythmia substrate anywhere else in the heart,
is more permanent than isolation approach, there may be
additional benefits with antral ablation including autonomic
modulation, etc., which may not be present with direct pul-
monary vein ablation. Furthermore, subsequent prototypes
will allow the flexibility of ablating both or either and the
antrum and within the pulmonary vein itself.
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